Zydus receives USFDA approval for initiating Phase I clinical trials of ‘ZYDPLA1’

23 Oct 2013 Evaluate

Zydus Cadila, an innovative global pharmaceutical company, has received an approval for Phase I clinical trial from the USFDA for ZYDPLA1 - a next generation, long-acting DPP-4 Inhibitor. ZYDPLA1 is an orally active, small molecule NCE, discovered and developed by the Zydus Research Centre, the NCE research wing of Zydus.

ZYDPLA1 is a novel compound in the Gliptin class of anti-diabetic agents. It works by blocking the enzyme Dipeptidyl Peptidase-4 (DPP-4), which inactivate the Incretin hormone GLP-1.

Currently, all available DPP-4 inhibitors are dosed once-daily, ZYDPLA1 with a once-a-week dosing regimen, would provide diabetic patients with a more convenient treatment alternative, ZYDPLA1 will offer sustained action, which will result, in an improved efficacy profile.

Zydus Lifesciences Share Price

884.85 8.75 (1.00%)
22-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1634.40
Dr. Reddys Lab 1217.15
Cipla 1371.55
Zydus Lifesciences 884.85
Lupin 2165.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×